news-pressrelease

Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to ‘Off-the-Shelf’ CAR-T Platform

Tessa Therapeutics today announced the execution of an exclusive agreement with Baylor College of Medicine…

Continue Reading

Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and Exposition

Tessa Therapeutics today announced that three abstracts reporting data from clinical trials investigating the company’s…

Continue Reading

Tessa Therapeutics to Present at the Stifel Healthcare Conference 2022

Tessa Therapeutics today announced that Thomas Willemsen, President and CEO and Dr. Ivan D. Horak,…

Continue Reading

Tessa Therapeutics to Participate in 2nd Annual Needham Biotech Private Company 1×1 Forum

Tessa Therapeutics today announced that Thomas Willemsen, President and CEO, Wilson W. Cheung, Chief Financial…

Continue Reading

Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf Therapies” Category at Asia-Pacific Cell & Gene Therapy Excellence Awards 2022

Tessa Therapeutics today announced that the company will host a scientific session during the SDCT-REMEDIS…

Continue Reading

Tessa Therapeutics Appoints Thomas Willemsen as President and CEO

Tessa Therapeutics today announced the appointment of Thomas Willemsen as its President and Chief Executive…

Continue Reading

Tessa Therapeutics Doses First Patient in Phase 1b Clinical Trial Investigating TT11 in Combination with Nivolumab for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma (cHL)

Tessa Therapeutics today announced that the company will host a scientific session during the SDCT-REMEDIS…

Continue Reading

Tessa Therapeutics to Host Scientific Session on CD30 CAR-T targeting of CD30+ Lymphomas at the SDCT-REMEDIS Cell Therapy Conference 2022

Tessa Therapeutics today announced that the company will host a scientific session during the SDCT-REMEDIS…

Continue Reading

Tessa Therapeutics Completes US$126 Million Financing Led by Polaris Partners

Proceeds to fund clinical development of Tessa’s autologous (TT11) and allogeneic (TT11X) cell therapy programs.…

Continue Reading

Tessa Therapeutics Appoints Wilson W. Cheung as Chief Financial Officer

Tessa Therapeutics today announced the appointment of Wilson W. Cheung as its chief financial officer…

Continue Reading